Mitsuru Koizumi1,2, Tsuneo Saga3, Masayuki Inubushi3, Toshimitsu Fukumura4, Kyosan Yoshikawa5, Naoyoshi Yamamoto6, Mio Nakajima6, Toshio Sugane6, Masayuki Baba6. 1. Diagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. mitsuru@nirs.go.jp. 2. Molecular Imaging Center, National Institute of Radiological Sciences, Anagawa 4-9-1, Inageku, Chiba, Japan. mitsuru@nirs.go.jp. 3. Diagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. 4. Molecular Probe, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. 5. Molecular Imaging Center and Clinical Diagnosis Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. 6. Clinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Abstract
PURPOSE: The aim of this study was to investigate the change of 3'-[¹⁸F]fluoro-3'-deoxy-L: -thymidine (¹⁸FLT) uptake in normal bone marrow (BM) after inevitable radiation. PROCEDURES: Twenty-one non-small cell lung cancer patients who received carbon ion radiotherapy (CIRT) were studied with ¹⁸FLT-positron emission tomography/computed tomography (PET/CT) at pre- and post-CIRT. Radiation dose was calculated by radiation planning. Irradiated BM was divided into three groups (<10% of maximum dose, 10-30%, and >30%). RESULTS: ¹⁸FLT uptake clearly decreased at >10% irradiated areas and mildly decreased at <10% areas. ¹⁸FLT uptake was lowest just after CIRT, somewhat increased at 3 months, and remained unchanged for more than 1 year. There was no significant difference between 10-30% and >30% areas. CONCLUSION: ¹⁸FLT revealed that BM function decreased by small dose such as <4.2-4.4 GyE/1 fraction of CIRT and is eradicated by >4.2-4.4 GyE/1 fraction.
PURPOSE: The aim of this study was to investigate the change of 3'-[¹⁸F]fluoro-3'-deoxy-L: -thymidine (¹⁸FLT) uptake in normal bone marrow (BM) after inevitable radiation. PROCEDURES: Twenty-one non-small cell lung cancerpatients who received carbon ion radiotherapy (CIRT) were studied with ¹⁸FLT-positron emission tomography/computed tomography (PET/CT) at pre- and post-CIRT. Radiation dose was calculated by radiation planning. Irradiated BM was divided into three groups (<10% of maximum dose, 10-30%, and >30%). RESULTS: ¹⁸FLT uptake clearly decreased at >10% irradiated areas and mildly decreased at <10% areas. ¹⁸FLT uptake was lowest just after CIRT, somewhat increased at 3 months, and remained unchanged for more than 1 year. There was no significant difference between 10-30% and >30% areas. CONCLUSION: ¹⁸FLT revealed that BM function decreased by small dose such as <4.2-4.4 GyE/1 fraction of CIRT and is eradicated by >4.2-4.4 GyE/1 fraction.
Authors: S J Martin; J A Eisenbarth; U Wagner-Utermann; W Mier; M Henze; H Pritzkow; U Haberkorn; M Eisenhut Journal: Nucl Med Biol Date: 2002-02 Impact factor: 2.408
Authors: Sarah Everitt; Rodney J Hicks; David Ball; Tomas Kron; Michal Schneider-Kolsky; Tania Walter; David Binns; Michael Mac Manus Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-20 Impact factor: 7.038
Authors: David C P Cobben; Bernard F A M van der Laan; Bram Maas; Willem Vaalburg; Albert J H Suurmeijer; Harald J Hoekstra; Pieter L Jager; Philip H Elsinga Journal: J Nucl Med Date: 2004-02 Impact factor: 10.057
Authors: Yusuf Menda; Laura L Boles Ponto; Kenneth J Dornfeld; Timothy J Tewson; G Leonard Watkins; Michael K Schultz; John J Sunderland; Michael M Graham; John M Buatti Journal: J Nucl Med Date: 2009-06-12 Impact factor: 10.057